In this report we combine the emergence of A2AR as a target for PD drug development with the growing realization that magnetic exposure legitimately modulates physiological processes in vivo in ways that may be therapeutically beneficial [49]–[52] (overall, more than 40 randomized controlled trials of magnetic therapy for more than 30 clinical indications have been reported [53]) to show that SMF exposure reproduces the effects of A2AR antagonists over a gamut of PD-relevant endpoints in PC12 cells. This evidence concerns the gene ADORA2A and Parkinson disease.